NRXP · NRX Pharmaceuticals, Inc. · Executive Compensation
$2.49
+0.09 (+3.75%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$107.81M
Shares
43.30M
Volume · Oct 23
840.3K
Avg daily vol (3M)
880.95K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman and Chief Scientist | $630,198 |
| Richard Narido | Chief Financial Officer | $298,015 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jonathan Javitt | Chairman and Chief Scientist | $873,696 |
| Stephen Willard | Chief Executive Officer | $799,871 |
| Richard Narido | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Taylor | Class I director | Appointed | 2026-03-24 |
| Chaim Hurvitz | Class I director | Appointed | 2026-03-24 |
| Joseph M. Casper | Chief Operating Officer | Appointed | 2026-02-02 |
| Janet Rehnquist | Board | Resigned | 2025-01-22 |
| Mike Taylor | Class I member of the Board of Directors | Appointed | 2025-01-22 |
| Janet Rehnquist | member of the Board of Directors | Resigned | 2025-01-14 |
| Michael Abrams | Chief Financial Officer | Appointed | 2024-11-20 |
| Jonathan Javitt | Interim Chief Executive Officer | Appointed | 2024-10-11 |
| Stephen Willard | Chief Executive Officer | Resigned | 2024-10-11 |
| Dr. Dennis McBride | member of the Board of Directors | Appointed | 2024-06-20 |
| Janet Rehnquist | Class II member of the Company's board of directors | Appointed | 2023-12-29 |
| Seth Van Voorhees | Chief Financial Officer | Resigned | 2023-09-14 |
| Richard Narido | Interim Chief Financial Officer | Appointed | 2023-09-14 |
| Robert Besthof | Head of Operations and Chief Commercial Officer | Resigned | 2023-02-23 |
| Alessandra Daigneault | Chief Corporate Officer, General Counsel and Corporate Secretary | Resigned | 2022-07-28 |
| Stephen Willard | member of the Board of Directors | Appointed | 2022-07-15 |
| Stephen Willard | Chief Executive Officer ("CEO") | Appointed | 2022-07-15 |
Leadership
- Jonathan C. Javitt CEO, Chairman, Board Member
- Jonathan Javitt CEO, Chairman
- Stephen Willard CEO
- Bennett Kim CFO, Board Member
- Dr. Seth Van Voorhees CFO
- Ira Strassberg CFO
- Michael Abrams CFO
- William Fricker CFO
- Joseph Casper COO
- Joseph M. Casper COO
- Alessandra Daigneault General Counsel
- Chaim Hurvitz Board Member
- Daniel Troy Board Member
- Dennis McBride Board Member
- Dr. Dennis McBride Board Member
- Herbert "H.R." McMaster Board Member
- Janet Rehnquist Board Member
- Michael Taylor Board Member
- Mike Taylor Board Member
- Patrick J. Flynn Board Member